| Literature DB >> 28859436 |
Dana S Clutter1, Shuntai Zhou2, Vici Varghese1, Soo-Yon Rhee1, Benjamin A Pinsky1,3, W Jeffrey Fessel4, Daniel B Klein5, Ean Spielvogel2, Susan P Holmes6, Leo B Hurley7, Michael J Silverberg7, Ronald Swanstrom2, Robert W Shafer1.
Abstract
Minority variant human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations are associated with an increased risk of virological failure during treatment with NNRTI-containing regimens. To determine whether individuals to whom variants with isolated NNRTI-associated drug resistance were transmitted are at increased risk of virological failure during treatment with a non-NNRTI-containing regimen, we identified minority variant resistance mutations in 33 individuals with isolated NNRTI-associated transmitted drug resistance and 49 matched controls. We found similar proportions of overall and nucleoside reverse transcriptase inhibitor-associated minority variant resistance mutations in both groups, suggesting that isolated NNRTI-associated transmitted drug resistance may not be a risk factor for virological failure during treatment with a non-NNRTI-containing regimen.Entities:
Keywords: HIV-1; antiretroviral therapy; drug resistance; minority variant; next-generation sequencing
Mesh：
Substances：
Year: 2017 PMID： 28859436 PMCID： PMC5853472 DOI： 10.1093/infdis/jix338
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226